No Data
No Data
Compass Therapeutics, Inc.'s (NASDAQ:CMPX) Institutional Shareholders Had a Great Week as One-year Returns Increased After a 28% Gain Last Week
Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating
Compass Therapeutics Advances Tovecimig, CTX-10726 In New Trials
H.C. Wainwright Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $10
Express News | HC Wainwright & Co. Maintains Buy on Compass Therapeutics, Maintains $10 Price Target
Compass Therapeutics: Strong Growth Potential Bolstered by Upcoming Milestones and Strategic Focus